Contingencies of UTX/KDM6A Action in Urothelial Carcinoma.
COMPASS complex
MLL
RNA-sequencing
UTX
bladder cancer
chromatin regulator
histone demethylase
histone methylation
nuclear localization
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 Apr 2019
04 Apr 2019
Historique:
received:
28
02
2019
revised:
28
03
2019
accepted:
02
04
2019
entrez:
17
4
2019
pubmed:
17
4
2019
medline:
17
4
2019
Statut:
epublish
Résumé
The histone demethylase Ubiquitously Transcribed Tetratricopeptide Repeat Protein X-Linked (UTX/KDM6A) demethylates H3K27me2/3 at genes and enhancers and is often inactivated by mutations in urothelial carcinoma (UC). The consequences of its inactivation are however poorly understood. We have investigated the consequences of moderate UTX overexpression across a range of UC cell lines with or without mutations in
Identifiants
pubmed: 30987376
pii: cancers11040481
doi: 10.3390/cancers11040481
pmc: PMC6520694
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Wilhelm Sander-Stiftung
ID : 2016.038.1
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
J Virol. 1999 Apr;73(4):2613-21
pubmed: 10074106
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Protoc. 2007;2(6):1445-57
pubmed: 17545981
Science. 2007 Oct 19;318(5849):447-50
pubmed: 17761849
Nature. 2007 Oct 11;449(7163):689-94
pubmed: 17851529
EMBO J. 2013 Apr 17;32(8):1075-86
pubmed: 23503590
Mol Cell Biol. 2013 May;33(10):2067-77
pubmed: 23508102
Stem Cells. 2014 Apr;32(4):974-82
pubmed: 24357085
FEBS Lett. 2014 Aug 25;588(17):3000-7
pubmed: 24928441
Nature. 2014 Oct 23;514(7523):513-7
pubmed: 25132549
Clin Cancer Res. 2014 Sep 15;20(18):4935-48
pubmed: 25225064
Biochem J. 2015 Jan 1;465(1):103-14
pubmed: 25247810
Blood. 2015 Jan 1;125(1):13-21
pubmed: 25320243
Mol Cancer. 2015 May 21;14:108
pubmed: 25994132
PLoS One. 2015 Sep 10;10(9):e0137110
pubmed: 26355749
Mol Cancer Ther. 2016 Feb;15(2):299-312
pubmed: 26772204
Genes Dev. 2016 Mar 1;30(5):508-21
pubmed: 26944678
Oncotarget. 2016 Sep 27;7(39):63252-63260
pubmed: 27533081
Sci Rep. 2016 Dec 07;6:38531
pubmed: 27924948
Bladder Cancer. 2016 Oct 27;2(4):449-463
pubmed: 28035326
Sci Transl Med. 2017 Feb 22;9(378):
pubmed: 28228601
Oncogene. 2017 Sep 28;36(39):5497-5511
pubmed: 28534508
Nucleic Acids Res. 2018 Jan 4;46(D1):D503-D508
pubmed: 29106588
Cancer Cell. 2017 Nov 13;32(5):701-715.e7
pubmed: 29136510
Int J Biochem Cell Biol. 2018 Apr;97:78-82
pubmed: 29421189
Cells. 2018 Mar 02;7(3):null
pubmed: 29498679
Cancer Cell. 2018 Mar 12;33(3):512-526.e8
pubmed: 29533787
Nat Genet. 2018 Jun;50(6):883-894
pubmed: 29736013
Cell. 2018 Aug 9;174(4):1033
pubmed: 30096301
Clin Cancer Res. 2019 Apr 15;25(8):2458-2470
pubmed: 30593515
Int J Cancer. 2019 Aug 1;145(3):614-620
pubmed: 30628063
Cancer Cell. 2019 Feb 11;35(2):168-176
pubmed: 30753822
J Virol. 1998 Nov;72(11):8873-83
pubmed: 9765432